MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MoonLake Immunotherapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-15.16 Mil. MoonLake Immunotherapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, MoonLake Immunotherapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, MoonLake Immunotherapeutics's current FCF Yield % is -1.96%.

The historical rank and industry rank for MoonLake Immunotherapeutics's FCF Margin % or its related term are showing as below:

MLTX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

MoonLake Immunotherapeutics FCF Margin % Historical Data

The historical data trend for MoonLake Immunotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics FCF Margin % Chart

MoonLake Immunotherapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

MoonLake Immunotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of MoonLake Immunotherapeutics's FCF Margin %

For the Biotechnology subindustry, MoonLake Immunotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's FCF Margin % falls into.

MoonLake Immunotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MoonLake Immunotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-43.063	/	0
	=	%

MoonLake Immunotherapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-15.16	/	0
	=	%

MoonLake Immunotherapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MLTX:Mexico

Address

Dorfstrasse 29, Zug, CHE, 6300

Website

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Executives

Matthias Bodenstedt	officer: Chief Financial Officer	DORFSTRASSE 29, ZUG V8 6300
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge	director	DORFSTRASSE 29, ZUG V8 6300
Kristian Reich	officer: Chief Scientific Officer	DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge	director, officer: Chief Executive Officer	DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il	director, 10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier	director	DORFSTRASSE 29, ZUG V8 6300
Spike Loy	director	DORFSTRASSE 29, ZUG V8 6300
Kara Lassen	director	DORFSTRASSE 29, ZUG V8 6300